Gap in Regulating Biotech Drug Copies Prompts WHO to Step in

Share this post

Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike – but uneven regulation has created a lopsided market.
Reuters Health Information

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply